association between polymorphisms in xrcc1 gene and clinical outcomes of patients with lung cancer a meta-analysisxrcc1基因的多态性与肺癌患者临床结果的荟萃分析.pdfVIP

Cui et al. BMC Cancer 2012, 12:71 /1471-2407/12/71 RESEARCH ARTICLE Open Access Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis Zhigang Cui1†, Zhihua Yin2,3†, Xuelian Li2,3, Wei Wu2,3, Peng Guan2,3 and Baosen Zhou2,3,4* Abstract Background: X-ray repair cross-complementing group 1 (XRCC1) protein plays an important role in the repair of DNA damage and adducts. Single nucleotide polymorphisms (SNPs) of XRCC1 are suspected to have some relationship with response to chemotherapy and overall survival of lung cancer. This meta-analysis aimed to summarize published data on the association between the commonest SNPs of XRCC1 (Arg194Trp, C T, rs1799782 and Arg399Gln, G A, rs25487) and clinical outcome of lung cancer patients. Methods: We retrieved the relevant articles from PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases. Studies were selected using specific inclusion and exclusion criteria. Primary outcomes included objective response (i.e., complete response + partial response vs. progressive disease + stable disease) and overall survival (OS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were estimated. All analyses were performed using the Stata software. Results: Twenty-two articles were included in the present analysis. XRCC1 Arg194Trp and Arg399Gln polymorphisms were significantly associated with response to treatment in lung cancer patients. Patients with C/T genotype, T/T genotype and minor variant T allele at Arg194Trp were more likely to respond to platinum-based chemotherapy compared with those with C/C genotype (C/T vs. C/C: OR, 2.54; 95%CI, 1.95-3.31; T/T vs. C/C: OR, 2.06; 95%CI, 1.39-3.06; C/T+T/T vs. C/C: OR, 2.42; 95% CI, 1.88-3.10). For XRCC1 Arg399Gln, G/A genotype, A/A